ALNY stock soars 62% in a year, driven by increasing Amvuttra and Givlaari sales. Its ongoing collaboration deals with RHHBY, NVS and REGN are progressing well.

Pliant follows in the footsteps of Acelyrin, which also enacted a stockholder rights program on Thursday to protect ...

H.C. Wainwright & Co. initiates a Buy rating on Perspective Therapeutics, citing promising cancer radiotherapy assets.

CRISPR Therapeutics' stock faces challenges with slow Casgevy adoption and competition. See how CRSP stock remains a cautious ...

The bioengineered protein drugs market is experiencing a paradigm shift, with pharmaceutical and biotech companies leveraging ...

Biologics Licensing Application (BLA) for clemidsogene lanparvovec (RGX-121) submitted and on track for potential FDA approval 2H 2025; strategic partnership with Nippon Shinyaku aims to expand ...

Here is how the Barron’s Roundtable members’ picks performed. Find investment ideas for your portfolio with the latest stock picks from Barron’s below. These picks are the product of the ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

The drug is therapeutically equivalent to Novartis' Votrient... ICAI to Review IndusInd Bank Financials Amid Accounting Discrepancies The ICAI may review IndusInd Bank's financial statements after ...